Bill Expands AUD Research for Veterans, Elevates Adial’s AD04 Potential
H.R. 7091 expands R&D eligibility to include Alcohol Use Disorder and backs non-abstinence therapies under updated federal recovery standards. Adial’s lead investigational therapy AD04, a genetically targeted serotonin-3 antagonist aimed at reducing heavy drinking, could gain federal support and funding as veterans’ treatment access widens.
1. Legislation Expands AUD Research Inclusion
H.R. 7091 designates Alcohol Use Disorder as eligible for expanded research and development, incorporating non-abstinence based endpoints such as harm reduction and reductions in heavy drinking under the federal definition of recovery.
2. Policy Aligns with Adial’s AD04 Strategy
The bill’s emphasis on investigational therapies that reduce heavy drinking directly supports the clinical design of AD04, a genetically targeted serotonin-3 receptor antagonist aiming to lower heavy drinking days in veterans.
3. Potential Implications for Adial
By reinforcing federal backing and possible grant opportunities for emerging AUD treatments in veterans, H.R. 7091 could accelerate Adial’s Phase 3 program planning and enhance AD04’s market prospects within a veteran population where 40% experience AUD.